Rubicon Research Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

The inspection was carried out from 29 June to 3 July 2026 and marked the first US FDA review of the facility since its acquisition by the company last year. Rubicon Research said that during the 12 months following the acquisition, it completed the integration of the facility, implemented its quality management systems, and fulfilled regulatory filing requirements that led to the inspection.

At the conclusion of the inspection, the US FDA issued a Form 483 with two observations. The company clarified that the observations are procedural in nature and do not relate to data integrity. It added that it is confident of working closely with the regulator to address the observations and complete the evaluation process in a timely manner.

Rubicon Research said a successful outcome of the inspection, achieved a little over a year after acquiring the facility, would reflect its strong quality and compliance culture and reinforce its regulatory track record.

The company also reiterated its earlier guidance and stated that it remains confident of ramping up commercial operations at the facility from the first quarter of calendar year 2027.

Rubicon Research is a pharmaceutical formulations company focused on innovation-led research and development, with a growing portfolio of specialty products and drug?device combination offerings aimed at regulated markets.

Rubicon Research surged 12.55% to Rs 1,130 after the company?s consolidated net profit soared 100% to Rs 76.78 crore on a 43.49% increase in revenue from operations to Rs 513.91 crore in Q4 FY26 over Q4 FY25.

The counter jumped 4.69% to Rs 1,363.80 on the BSE.

Powered by Capital Market - Live News

Profit before tax (PBT) jumped 93.26% YoY to Rs 98.68 crore in Q4 FY26.

EBITDA stood at Rs 121.3 crore in Q4 FY26, up 67.2% compared with Rs 72.6 crore in Q4 FY25. EBITDA margin expanded to 23.6% in Q4 FY26 as against 20.3% in Q4 FY25.

In dollar terms, revenue rose 35% to $56 million in Q4 FY26 from $41 million in Q4 FY25. Approximately 98% of the company's revenue is denominated in US dollars.

On full year basis, the company?s consolidated net profit jumped 83.63% to Rs 246.73 crore in FY26 compared with Rs 134.36 crore in FY25. Revenue from operations climbed 36.57% to Rs 1,753.95 crore in FY26 from Rs 1,284.27 crore posted in FY25.

Meanwhile, the company?s board recommended a dividend of Rs 1.50 per equity share of the face value of Re 1 each fully paid up, for the financial year ended March 31, 2026.

Rubicon Research is a pharmaceutical formulations company focused on innovation-led research and development, with a growing portfolio of specialty products and drug?device combination offerings aimed at regulated markets.

Powered by Capital Market - Live News

Rubicon Research has allotted 2,90,626 equity shares under ESOS on 29 May 2026. Consequently, the issued, subscribed and paid-up equity share capital of the Company stands increased to Rs 16,53,82,750 comprising of 16,53,82,750 equity shares of face value Rs 1 each.

Rubicon Research will hold a meeting of the Board of Directors of the Company on 29 May 2026.